EU/3/12/1098

About

On 24 January 2013, orphan designation (EU/3/12/1098) was granted by the European Commission to Enpharma, United Kingdom, for encapsulated human retinal pigment epithelial cell line transfected with plasmid vector expressing human ciliary neurotrophic factor for treatment of retinitis pigmentosa.

The sponsor's address was updated in May 2018.

The sponsor’s address was updated in October 2020.

Key facts

Active substance
Encapsulated human retinal pigment epithelial cell line transfected with plasmid vector expressing human ciliary neurotrophic factor
Disease / condition
Treatment of retinitis pigmentosa
Date of first decision
24/01/2013
Outcome
Positive
EU designation number
EU/3/12/1098

Review of designation

The Committee for Orphan Medicinal Products reviews the orphan designation of a product if it is approved for marketing authorisation.

Sponsor's contact details

Enpharma Ltd
264 Banbury Road
Oxford OX2 7DY
United Kingdom
Tel: +44 1993 880089
E-mail: mail@enpharma.com

Patients' organisations

For contact details of patients’ organisations whose activities are targeted at rare diseases, see:

  • European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.

  • Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe.

How useful was this page?

Add your rating